CervoMed’s neflamapimod continues to show promise in dementia with Lewy bodies

28 July 2025

Shares in CervoMed (Nasdaq: CRVO) were up 6% Monday lunchtime after the US company announced positive 32-week data from the extension phase of the Phase IIb RewinD-LB trial showing that oral neflamapimod continues to slow disease progression and demonstrate an effect on a plasma marker of neurodegeneration in dementia with Lewy bodies (DLB).

The disease progression analyses were featured in two presentations during the Alzheimer’s Association International Congress 2025 (AAIC) on Sunday.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK